Search All News
In a phase three clinical trial, sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment.
Anil K. Rustgi, MD, an expert in gastrointestinal tumors, will join Columbia University Irving Medical Center and NewYork-Presbyterian as director of the Herbert Irving Comprehensive Cancer Center.
- January 12, 2017
Collaboration will investigate a system biology approach to identifying treatment options for patients with advanced gastrointestinal stromal tumors (GIST).
- December 22, 2016
Columbia University researchers have created a user-friendly program that rapidly predicts which genes are implicated in an individual’s cancer and recommends treatments.
- December 16, 2016
Researchers have found that blocking nerve growth factor inhibits the formation of stomach cancers, according to a study in mice.
- December 5, 2016
In a phase 1 study, eight out of 12 patients with relapsed and/or refractory blood cancers responded to a combination of two common chemotherapy drugs.
- September 14, 2016
In mice studies, targeting the SET protein revives p53, a potent tumor suppressor, and prevents cancer growth.
- July 21, 2016
Adding a new drug called olaratumab to traditional chemotherapy increased survival in sarcoma patients, researchers at Columbia University Medical Center have found.
- July 15, 2016
The three-dimensional structure could help researchers develop novel therapies and diagnostic tools for diseases that are caused by a malfunction in calcium adsorption.
- July 12, 2016
According to a new report published in JAMA Oncology, women with BRCA1 mutations have a higher risk of developing an aggressive type of uterine cancer.